<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7612148</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6787</journal-id>
<journal-id journal-id-type="nlm-ta">Psychoneuroendocrinology</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychoneuroendocrinology</journal-id>
<journal-title-group>
<journal-title>Psychoneuroendocrinology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0306-4530</issn>
<issn pub-type="epub">1873-3360</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29544191</article-id>
<article-id pub-id-type="pmc">5901899</article-id>
<article-id pub-id-type="doi">10.1016/j.psyneuen.2018.02.007</article-id>
<article-id pub-id-type="manuscript">NIHMS952796</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mosher</surname>
<given-names>Laura J</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Godar</surname>
<given-names>Sean C</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morissette</surname>
<given-names>Marc</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McFarlin</surname>
<given-names>Kenneth M</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scheggi</surname>
<given-names>Simona</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gambarana</surname>
<given-names>Carla</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fowler</surname>
<given-names>Stephen C</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Di Paolo</surname>
<given-names>Thérèse</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bortolato</surname>
<given-names>Marco</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City (UT)</aff>
<aff id="A2">
<label>2</label>Dept. of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence (KS)</aff>
<aff id="A3">
<label>3</label>Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, CHUL, Quebec City, Quebec, Canada</aff>
<aff id="A4">
<label>4</label>Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy</aff>
<aff id="A5">
<label>5</label>Faculty of Pharmacy, Laval University, Quebec City, Quebec, Canada</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Marco Bortolato, MD PhD, Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, L.S. Skaggs Hall, 30 S 2000 E, Salt Lake City, UT 84112, <email>marco.bortolato@utah.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>Conflict of Interest</p>
<p>The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2019</year>
</pub-date>
<volume>91</volume>
<fpage>95</fpage>
<lpage>104</lpage>
<!--elocation-id from pubmed: 10.1016/j.psyneuen.2018.02.007-->
<abstract>
<p id="P1">The enzyme steroid 5α-reductase 2 (5αR2) catalyzes the conversion of testosterone into the potent androgen 5α-dihydrotestosterone. Previous investigations showed that 5αR2 is expressed in key brain areas for emotional and socio-affective reactivity, yet the role of this enzyme in behavioral regulation remains mostly unknown. Here, we profiled the behavioral characteristics of 5αR2 heterozygous (HZ) and knockout (KO) mice, as compared with their wild-type (WT) littermates. While male 5αR2 KO mice displayed no overt alterations in motoric, sensory, information-processing and anxiety-related behaviors, they exhibited deficits in neurobehavioral correlates of dominance (including aggression against intruders, mating, and tube dominance) as well as novelty-seeking and risk-taking responses. Furthermore, male 5αR2 KO mice exhibited reduced D<sub>2</sub>-like dopamine receptor binding in the shell of the nucleus accumbens - a well-recognized molecular signature of social dominance. Collectively, these results suggest that 5αR2 is involved in the establishment of social dominance and its behavioral manifestations. Further studies are warranted to understand how the metabolic actions of 5αR2 on steroid profile may be implicated in social ranking, impulse control, and the modulation of dopamine receptor expression in the nucleus accumbens.</p>
</abstract>
<kwd-group>
<kwd>5α-reductase</kwd>
<kwd>transgenic mice</kwd>
<kwd>dominance</kwd>
<kwd>aggression</kwd>
<kwd>novelty seeking</kwd>
<kwd>risk taking</kwd>
<kwd>dopamine</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>